Show newer

SARS-CoV-2 testing in the Slovak Republic from March 2020 to September 2022 - summary of the pandemic trends medrxiv.org/content/10.1101/20

A note on p-value multiple-testing adjustment for two-step genome-wide gene-environment interactions scans medrxiv.org/content/10.1101/20

Influence of sex hormone use on sleep architecture in a transgender cohort: findings from the prospective RESTED study medrxiv.org/content/10.1101/20

COVID-19 Impact in Crohn Disease Patients Underwent Autologous Hematopoietic Stem Cell Transplantation medrxiv.org/content/10.1101/20

How does corruption influence health system efficiency? A case study of two counties in Kenya medrxiv.org/content/10.1101/20

The Mexican dataset of a repetitive transcranial magnetic stimulation clinical trial on cocaine use disorder patients: SUDMEX TMS medrxiv.org/content/10.1101/20

Design and Analysis Heterogeneity in Observational Studies of COVID-19 Booster Effectiveness: A Review and Case Study medrxiv.org/content/10.1101/20

Prognostic impact of atrial cardiomyopathy: Long-term follow-up of patients with and without low-voltage areas following atrial fibrillation ablation medrxiv.org/content/10.1101/20

Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US healthcare system medrxiv.org/content/10.1101/20

Prevalence, knowledge, causes, and practices of self-medication during the COVID-19 pandemic in Bangladesh: A cross-sectional survey medrxiv.org/content/10.1101/20

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies medrxiv.org/content/10.1101/20

The protein profiles of postoperative incision infection after plate internal fixation of calcaneal fractures medrxiv.org/content/10.1101/20

Machine Learning Interpretability Methods to Characterize Brain Network Dynamics in Epilepsy medrxiv.org/content/10.1101/20

Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care medrxiv.org/content/10.1101/20

Show older
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.